Q2
CLRB — Q2 2026 Financial Report Analysis
Cellectar’s Q2 loss widened 27% to $6.9M as R&D nearly doubled for the iopofosine Phase 3 start; a $31.7M May raise lifted cash to $34.0M, but runway only reaches Q2 2027 and the going-concern warning stays.